Collegium (COLL) | Financial Analysis & Statements
Collegium Pharmaceutical Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
205.4M
Gross Profit
128.4M
62.49%
Operating Income
60.7M
29.56%
Net Income
17.0M
8.26%
EPS (Diluted)
$0.46
Balance Sheet Metrics
Total Assets
1.7B
Total Liabilities
1.4B
Shareholders Equity
301.7M
Debt to Equity
4.49
Cash Flow Metrics
Operating Cash Flow
96.1M
Free Cash Flow
122.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Collegium Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 780.6M | 631.4M | 566.8M | 463.9M | 276.9M |
| Cost of Goods Sold | 317.3M | 254.1M | 240.6M | 254.4M | 126.3M |
| Gross Profit | 463.3M | 377.3M | 326.2M | 209.5M | 150.6M |
| Gross Margin % | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% |
| Operating Expenses | |||||
| Research & Development | - | 0 | 0 | 4.0M | 9.5M |
| Selling, General & Administrative | 284.8M | 210.4M | 159.2M | 172.2M | 119.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 284.8M | 210.4M | 159.2M | 176.2M | 128.4M |
| Operating Income | 178.5M | 167.0M | 167.0M | 33.3M | 22.2M |
| Operating Margin % | 22.9% | 26.4% | 29.5% | 7.2% | 8.0% |
| Non-Operating Items | |||||
| Interest Income | 11.3M | 14.0M | 15.6M | 1.0M | 12.0K |
| Interest Expense | 82.3M | 74.0M | 83.3M | 63.2M | 21.0M |
| Other Non-Operating Income | -14.8M | -8.4M | -23.5M | - | -4.6M |
| Pre-tax Income | 92.6M | 98.6M | 75.7M | -28.8M | -3.4M |
| Income Tax | 29.7M | 29.4M | 27.6M | -3.8M | -74.9M |
| Effective Tax Rate % | 32.1% | 29.8% | 36.4% | 0.0% | 0.0% |
| Net Income | 62.9M | 69.2M | 48.2M | -25.0M | 71.5M |
| Net Margin % | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% |
| Key Metrics | |||||
| EBITDA | 415.8M | 350.1M | 331.8M | 173.3M | 91.1M |
| EPS (Basic) | $1.98 | $2.14 | $1.43 | $-0.74 | $2.05 |
| EPS (Diluted) | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 |
| Basic Shares Outstanding | 31706429 | 32273850 | 33741213 | 33829495 | 34936817 |
| Diluted Shares Outstanding | 31706429 | 32273850 | 33741213 | 33829495 | 34936817 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Collegium Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 231.3M | 70.6M | 238.9M | 173.7M | 186.4M |
| Short-term Investments | 155.4M | 92.2M | 71.6M | 0 | - |
| Accounts Receivable | 211.3M | 228.5M | 179.5M | 183.1M | 105.8M |
| Inventory | 40.9M | 35.6M | 32.3M | 46.5M | 17.4M |
| Other Current Assets | 3.2M | 2.7M | 93.0K | 57.0K | 27.0K |
| Total Current Assets | 691.4M | 482.3M | 537.6M | 420.0M | 315.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 25.8M | 27.1M | 27.1M | 28.2M | 23.5M |
| Goodwill | 961.4M | 1.2B | 689.4M | 834.9M | 268.7M |
| Intangible Assets | 669.5M | 891.4M | 421.7M | 567.5M | 268.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 133.8M | 107.4M | 28.1M | 26.6M | 80.7M |
| Total Non-Current Assets | 965.4M | 1.2B | 605.7M | 754.1M | 376.5M |
| Total Assets | 1.7B | 1.7B | 1.1B | 1.2B | 692.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 10.7M | 3.9M | 8.7M | 3.5M | 4.2M |
| Short-term Debt | 30.4M | 65.9M | 184.3M | 163.6M | 49.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 2.4M | 3.0M | - | - | - |
| Total Current Liabilities | 440.0M | 509.5M | 457.9M | 433.7M | 279.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 784.5M | 793.4M | 490.0M | 545.6M | 209.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | 1.2M | - | - | - |
| Total Non-Current Liabilities | 915.1M | 925.2M | 490.0M | 545.6M | 209.6M |
| Total Liabilities | 1.4B | 1.4B | 947.9M | 979.3M | 489.1M |
| Equity | |||||
| Common Stock | 41.0K | 40.0K | 38.0K | 37.0K | 36.0K |
| Retained Earnings | -101.1M | -164.0M | -233.2M | -281.3M | -256.3M |
| Treasury Stock | 222.5M | 197.5M | 137.4M | 61.9M | 42.9M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 301.7M | 228.8M | 195.4M | 194.8M | 202.9M |
| Key Metrics | |||||
| Total Debt | 814.9M | 859.3M | 674.3M | 709.2M | 258.8M |
| Working Capital | 251.4M | -27.3M | 79.7M | -13.7M | 36.0M |
Balance Sheet Composition
Collegium Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 62.9M | 69.2M | 48.2M | -25.0M | 71.5M |
| Depreciation & Amortization | 226.1M | 169.2M | 149.3M | 138.9M | 68.9M |
| Stock-Based Compensation | 41.9M | 32.4M | 27.1M | 22.9M | 24.3M |
| Working Capital Changes | 18.4M | -1.8M | 22.8M | 25.8M | -30.6M |
| Operating Cash Flow | 329.0M | 248.9M | 253.6M | 162.7M | 59.4M |
| Investing Activities | |||||
| Capital Expenditures | -1.7M | -1.7M | -461.0K | -1.6M | -1.9M |
| Acquisitions | 0 | -267.5M | 0 | -572.1M | 0 |
| Investment Purchases | -127.0M | -111.2M | -92.4M | 0 | 0 |
| Investment Sales | 65.2M | 92.6M | 22.0M | 0 | 0 |
| Investing Cash Flow | -63.5M | -287.8M | -70.8M | -573.7M | -1.9M |
| Financing Activities | |||||
| Share Repurchases | -25.1M | -60.0M | -75.0M | -14.1M | -47.9M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 565.2M | 313.2M | 235.2M | 517.7M | 0 |
| Debt Repayment | -635.6M | -305.7M | -301.1M | -75.0M | -50.0M |
| Financing Cash Flow | -115.9M | -71.7M | -149.3M | 424.6M | -102.0M |
| Free Cash Flow | 327.6M | 203.3M | 274.3M | 122.6M | 101.6M |
| Net Change in Cash | 149.6M | -110.5M | 33.5M | 13.6M | -44.5M |
Cash Flow Trend
Collegium Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.79
Forward P/E
4.82
Price to Book
3.42
Price to Sales
1.35
PEG Ratio
0.49
Profitability Ratios
Profit Margin
8.05%
Operating Margin
30.04%
Return on Equity
23.70%
Return on Assets
7.27%
Financial Health
Current Ratio
1.57
Debt to Equity
310.41
Beta
0.77
Per Share Data
EPS (TTM)
$1.73
Book Value per Share
$9.51
Revenue per Share
$24.62
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| COLL | 1.1B | 18.79 | 3.42 | 23.70% | 8.05% | 310.41 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Dynavax Technologies | 1.8B | 54.60 | 3.41 | -7.14% | -13.13% | 54.15 |
| Ani Pharmaceuticals | 1.8B | 24.08 | 3.10 | 16.16% | 8.87% | 116.19 |
| Perrigo Company plc | 1.6B | 2,818.00 | 0.55 | -38.66% | -33.51% | 131.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.






